GlassScriptPhysician profile
Roy J Durbin
NPI 1639130438
$2,271.42
in general payments reported to CMS, 2019-2025
34 companies · $22.05 in 2025
The $22.05 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $212 · 2021: $659 · 2022: $812 · 2023: $267 · 2024: $17.03 · 2025: $22.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.87 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $406.08 | 2020-2023 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $289.67 | 2019-2023 | Prolia, Evenity |
| Novo Nordisk INC | $136.55 | 2020-2023 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $132.31 | 2019-2023 | Veozah |
| Medtronic, INC. | $105.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $101.01 | 2019-2021 | |
| Amarin Pharma, INC. | $97.52 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $96.43 | 2021-2022 | |
| Lilly USA, LLC | $93.30 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.64 | 2020-2022 | |
| Glaxosmithkline, LLC. | $68.04 | 2022-2023 | Trelegy Ellipta |
| Abbott Laboratories | $62.28 | 2021-2023 | Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $56.43 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.69 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.30 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39.62 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.26 | 2021 | |
| Nestle Healthcare Nutrition INC. | $38.91 | 2021-2022 | |
| Dermira, INC. | $35.66 | 2020 | |
| Merck Sharp & Dohme LLC | $35.37 | 2021-2023 | Gardasil 9, Vaxelis, M-M-R II |
| Allergan, INC. | $35.33 | 2020-2022 | |
| Eisai INC. | $24.09 | 2020 | |
| Hologic Sales and Service, LLC | $23.50 | 2022 | |
| Boston Scientific Corporation | $22.05 | 2025 | General - Therapies |
| Si-Bone, INC. | $21.51 | 2021 | |
| Optinose US, INC. | $18.63 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.03 | 2021 | |
| Aimmune Therapeutics, INC. | $17.03 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $17.02 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.85 | 2020 | |
| Nevro Corp. | $16.63 | 2022 | |
| Grifols USA, LLC | $14.68 | 2022 | |
| Sanofi Pasteur INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Durbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.